Sentences with phrase «stem cell therapy company»

Stem Cell Therapy company presents a collection of stem cell - based therapy summaries for multiple diseases such as diabetes, liver disease, lung disease, osteoarthritis and more.

Not exact matches

HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy.

Geron was bigger and better funded than ACT, and it was the first company to be approved by the US Food and Drug Administration (FDA) to test a therapy in humans based on embryonic stem (ES) cells.

And a good outcome could encourage investment in other stem - cell therapy companies, says Bonfiglio, who is now managing partner at Proteus Venture Partners in Palo Alto, California.

The immediate payoff was a commercialization deal in age - related macular degeneration in which Pfizer became the first big pharma company to make a move into the use of embryonic stem cells as the basis for a tissue regeneration therapy.

Clinical trials that charge enrollees to participate are ostensibly aimed at giving patients early access to promising therapies — often in the fields of stem cells or aging reversal — that are too unusual or have too little profit potential to get funding from traditional sources such as companies, foundations, or the National Institutes of Health.

The biggest UK employers in industry are Smith & Nephew, a research company focused on wound care, and drug company Pfizer, whose research includes developing stem cell therapies for Crohn's disease.

Cynata Therapeutics Limited is an Australian clinical - stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus ™ stem cell technology platform.

San Diego, California, October 10, 2013 — ViaCyte, Inc. announced today that an update on the Company's progress toward a transformative stem cell - derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, Califorstem cell - derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, Califorcell - derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, Califorcell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, CaliforStem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, CaliforCell Meeting on the Mesa to be held October 14 - 16 in La Jolla, California.

I - Stem, the Institute for Stem cell Therapy and Exploration of Monogenic Diseases, has signed an agreement with Swissbased healthcare company Roche to use I - Stem's technologies in discovering novel therapies to treat devastating central nervous system (CNS) diseases such as Alzheimer's, schizophrenia, depression and anxiety.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

Making this even more historic, ViaCyte recently acquired the assets of BetaLogics, a company that for more than a decade has also been working toward a stem cell - derived therapy for diabetes.

A U.S. biotech company will attempt to resurrect 20 brain - dead patients by a combination of novel therapies involving brain stem cells.

HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy.

San Diego, California, October 29, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty fcompany focused on developing new approaches to treat major diseases through the application of a stem cell - derived cell therapy, announced today that the Company was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty fCompany was granted over 20 patents worldwide in 2013 thus far, three U.S. and twenty foreign.

Here I pick and overview the most interesting new companies in stem cell / cell therapy / regenerative medicine field.

The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

The company is utilizing regenerative cell therapy in situ approach by providing artificial niches for endogenous stem cells.

For only the second time, the Food and Drug Administration approved a company's request to test an embryonic stem cell - based therapy on human patients.

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product cancompany with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product canCompany's Phase 1/2 clinical trial of its VC - 01TM product candidate.

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follstem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follStem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

In Louisiana, the 4 - year - old TCA Cellular Therapy company has several ongoing FDA - approved clinical trials on humans, using patients» own stem cells to treat heart and vascular diseases.

«It has been rewarding to be a part of a company that has pioneered the development of stem cell therapy, including the development of technologies that hold promise for the treatment of diabetes,» said Lewis.

The Company's pluripotent stem cell - derived islet cell replacement therapy, the PEC - Direct ™ product candidate, has the potential to be a breakthrough treatment for high - risk type 1 diabetes.

One of the earliest to recognize the breadth and depth of potential stem cell therapies, Weissman founded two companies (SyStemix and StemCells, Inc.) and has been an outspoken proponent of cloning for research purposes.

Novocell, Inc. is a stem cell engineering company with research operations in San Diego, California and Athens, Georgia, dedicated to creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases.

Neurona is a cell therapy company founded by world class neural stem cell experts and focused on the discovery and development of disease - altering treatments for intractable neuropsychiatric disorders.

San Diego, CA (March 31, 2009)-- Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent 7,510,876 with claims covering human definitive endoderm cells, an essential cell for generating not only pancreatic type cells, which Novocell is developing for use as a cell therapy for diabetes, but also other endoderm lineage - derived tissues and organs such as lungs, intestine, liver, thymus and thyroid.

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.

The company is focusing on stem cells both as therapies and as tools for drug discovery.

Company Combines Leaders in Fields of Neuroscience and Stem Cell Biology to Develop Cell Therapies With Broad Potential to Treat Neurological Disease

In recent years, stem cell therapy, such as that offered by the Vet - Stem company, has been gaining momenstem cell therapy, such as that offered by the Vet - Stem company, has been gaining momenStem company, has been gaining momentum.

The company has used the licensed stem cell therapy to treat more than 2,500 horses and over 200 dogs with arthritis and tendon and ligament injuries.

California based Vet - Stem, a company that touts itself to be a global leader in veterinary regenerative medicine, has been using stem cell therapy in horses for three years and is now offering it to dStem, a company that touts itself to be a global leader in veterinary regenerative medicine, has been using stem cell therapy in horses for three years and is now offering it to dstem cell therapy in horses for three years and is now offering it to dogs.

Safari stands apart and is well ahead of the curve when it comes to stem cell therapy as compared to other veterinary hospitals or companies providing stem cell therapy to pets.

In December Jojo received stem cell therapy through VetStem, a Poway - based biomedical company.

That said however, if you have been diagnosed and been able to demonstrate that through stem cell therapy that you no longer suffer from myelofibrosis, we would be happy to «submit» your life insurance application to multiple insurance companies to see if their underwriting guidelines have changed.